|
1. Middleton RJ, Foley RN, Hegarty J, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 21:88-92, 2006.
2. Kuzminskis V, Skarupskiene I, Bumblyte IA, et al. Comparison of methods for evaluating renal function (Data of Kaunas University of Medicine Hospital in 2006, Medicina (Kaunas).;43 Suppl 1:46-51, 2007.
3. Filler G, Priem F, Lepage N, et al. Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem. 48:729-36, 2002.
4. Törner A, Odar-Cederlöf I, Kallner A, et al. Renal function in community-dwelling frail elderly. Comparison between measured and predicted glomerular filtration rate in the elderly and proposal for a new cystatin C-based prediction equation. Aging Clin Exp Res. 20:216-25, 2008.
5. Halacova M, Kotaska K, Kukacka J, et al Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin. J Clin Pharm Ther. 33:409-17, 2008.
6. Mazzara, A and D. Plaut AACC, Washington DC, 2008.
7. Onat A, Hergenç G, Sansoy V, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 168:81-9, 2003.
8. Scheffer PG, Teerlink T, Dekker JM, et al Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem. 54:1325-30, 2008.
9. Garvin P, Nilsson L, Carstensen J, et al Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE. 12;3(3):e1774, 2008.
10. Orbe J, Montero I, Rodríguez JA, et al Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J Thromb Haemost. 5:91-7, 2007.
11. Walt DR, Blicharz TM, Hayman RB, et al. Microsensor arrays for saliva diagnostics. Ann N Y Acad Sci. 1098:389-400, 2007.
12. Cleutjens KB, Faber BC, Rousch M, et al. Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling. J Clin Invest. 118:2675-7, 2008.
13. Claudon A, Vergnaud P, Valverde C, et al New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem. 54:1554-63, 2008.
14. Jang YY, Kim CY, Hwang TY, et al Reference interval of serum thyroid hormones in healthy Korean adults. J Prev Med Public Health. 41:128-34, 2008.
15. Hershman JM, Pekary AE, Berg L, et al. Serum thyrotropin and thyroid hormone levels in elderly and middle-aged euthyroid persons. J Am Geriatr Soc. 41:823-8, 1993.
16. Sauter ER, Wagner-Mann C, Ehya H, et al Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detect Prev. 2007;31(1):50-8.
17. Yildirim Y, Gunel N, Coskun U, et al. Serum big endothelin-1 levels in female patients with breast cancer. Int Immunopharmacol. 2008 Aug;8(8):1119-23
18. Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54.
19. Sokoll LJ, Wang Y, Feng Z, et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008 Aug;180(2):539-43.
20. Alsina MJ, Alvarez V, Barba N, et al. Preanalytical quality control program - an overview of results. Clin Chem Lab Med. 2008;46(6):849-54.
21. Antal-Szalmás P, Ivády G, Molnár A, et al "Turnaround time": a new parameter for the characterization of the overall efficacy of laboratory diagnostic processes. Orv Hetil. 2007 Jul 15;148(28):1317-27. Antal-Szalmás P, Ivády G, Molnár A, et al "Turnaround time": a new parameter for the characterization of the overall efficacy of laboratory diagnostic processes. Orv Hetil. 2007 Jul 15;148(28):1317-27
22. Serdar MA, Turan M, Cihan M. Rapid access to information resources in clinical biochemistry: medical applications of Personal Digital Assistants (PDA). Clin Exp Med. 2008 Jun;8(2):117-22.
23. Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008; 54:11-13. and
24. Warnick GR and K. Nakajima. Fasting versus Nonfasting Triglycerides: Implications for Laboratory Measurements. Clin Chem 2008; 54: 14-16.
25. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-316 and Nordestrgaad BG, Benn M, Schnohr P, Tybaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. JAMA 2007; 298: 299-308.
|